Prometheus Biosciences, Inc. (RXDX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Mark C. McKenna.
RXDX has IPO date of 2021-03-12, 97 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $9.56B.
Prometheus Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and companion diagnostics for inflammatory bowel diseases (IBD). The company's lead candidate, PRA023, is a humanized monoclonal antibody currently in Phase IIa clinical trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Prometheus maintains a robust pipeline including multiple therapeutic programs targeting different disease mechanisms in IBD and immune-mediated conditions, supported by strategic partnerships with leading pharmaceutical companies including Takeda, Dr. Falk Pharma, and Millennium Pharmaceuticals. Headquartered in San Diego, California, the company was incorporated in 2016 and formerly operated under the name Precision IBD, Inc. before rebranding to Prometheus Biosciences in October 2019.
